Open
友銘將自生技中心移轉一小分子化合物,做為腫瘤醫學開發的小分子首創新藥(不同藥物機制中的第一個新藥)。研發團隊由張嘉銘博士率領,預期於2023年進行人體臨床試驗。
Through the Value-Creation project funding, Famous Biotech will be granted a small compound from DCB that is the first-in-class molecule for oncology development.
Through the Value-Creation project funding, Famous Biotech will be granted a small compound from DCB that is the first-in-class molecule for oncology development.